The 57 references in paper E. Kropacheva S., O. Zemlyanskaya A., E. Panchenko P., A. Dobrovolsky B., E. Krivosheeva N., Е. Кропачева С., О. Землянская А., Е. Панченко П., А. Добровольский Б., Е. Кривошеева Н. (2017) “БЕЗОПАСНОСТЬ ДЛИТЕЛЬНОЙ ТЕРАПИИ ВАРФАРИНОМ: ЧАСТОТА КРОВОТЕЧЕНИЙ И КЛИНИЧЕСКИЕ ПРЕДИКТОРЫ ИХ РАЗВИТИЯ (результаты проспективного 15-летнего наблюдения) // SAFETY OF LONG-TERM THERAPY WITH WARFARIN: HEMORRHAGE FREQUENCY AND CLINICAL PREDICTORS (results of a prospective 15-year follow-up)” / spz:neicon:aterotromboz:y:2017:i:1:p:145-162

1
Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ, 2012.
(check this in PDF content)
2
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2 Suppl): e637S-68S. doi: 10.1378/chest.11-2306. pmid: 22315274.
(check this in PDF content)
3
Gorst-Rasmussen A, Lip GY, Larsen TB. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Pharmacoepidemiol Drug Saf, 2016, 25: 1236-1244.
(check this in PDF content)
4
Hylek EM, Evans-Molina C, Shea C et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation, 2007, 29, 115(21): 2689-96.
(check this in PDF content)
5
Hylek EM, Held C, Alexander JH et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol, 2011, 63(20): 2141-7.
(check this in PDF content)
6
White RH, McKittrick T, Takakuwa J et al. Management and prognosis of life-threatening bleeding during warfarin therapy. National Consortium of Anticoagulation Clinics. Arch Intern Med, 1996, 156(11): 1197-201.
(check this in PDF content)
7
Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J, 2012, 33(12): 1500-10.
(check this in PDF content)
8
Fihn SD, Callahan CM, Martin DC et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med, 1996, 124(11): 970-9.
(check this in PDF content)
9
Kakkar AK, Mueller I, Bassand JP et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). AHJ,2012, 163(1): 13-19.
(check this in PDF content)
10
Антитромботическая терапия у больных со стабильными проявлениями атеротромбоза. Российские рекомендации. Кардиоваскулярная терапия и профилактика, 2009, 8(6).
(check this in PDF content)
11
Lip GYH, Keshishian A, Kamble S et al. Real-world comparison of major bleeding risk among nonvalvul aratrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. Thrombosis and Haemostasis,2016, 116: 777-1002.
(check this in PDF content)
12
Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am CollCardiol, 2011, 57(2): 173-80.
(check this in PDF content)
13
Fang MC, Go AS, Chang Y et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am CollCardiol, 2011, 58(4): 395-401.
(check this in PDF content)
14
Gage BF, Yan Y, Milligan PE et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J, 2006, 151(3): 713-9.
(check this in PDF content)
15
Olesen JB, Lip GY, Hansen PR et al. Bleeding risk in ‘real world’ patients with atrial fibrillation: comparison of two establishedbleeding prediction schemes in a nationwide cohort. J Thromb Haemost, 2011, 9(8): 1460-7.
(check this in PDF content)
16
Apostolakis S, Lane DA, Buller H, Lip GY. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. Thromb Haemost, 2013, 110(5): 1074-9.
(check this in PDF content)
17
Marcucci M, Lip GY, Nieuwlaat R et al. Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey. Am J Med, 2014, 127(10): 979-986.
(check this in PDF content)
18
Mennuni MG, Halperin JL, Bansilal S et al. Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). Am J Cardiol,2015, 116(1): 37-42.
(check this in PDF content)
19
Морева О.В., Кропачева Е.С., Добровольский А.Б. и соавт. Факторы риска рецидива кровотечений при терапевтических значениях международного нормализованного отношения у больных, длительно получающих варфарин. Кардиология,
(check this in PDF content)
20
6, 56(2): 40-46. 20. Fihn SD, McDommel M, Matin D et al. Risk factors fоr complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Groop. Ann Intern Med,1993 Apr1, 118(7), 511-20,
(check this in PDF content)
21
Mhairi Copland, Walker I.D., Campbell R., “Oral Anticoagulation and Hemorrhagic Complications in an Elderly Population With Atrial Fibrillation” Arch Inter Med 2001, 161 61(17): 2125-8.
(check this in PDF content)
22
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med,1994, 154(13): 1449-1457.
(check this in PDF content)
23
Steffensen FH, Kristensen K, Ejlersen E et al. Major haemorrhagic complications during oral anticoagulant therapy in a Danish populationbased cohort. J Intern Med,1997, 242(6): 497-503.
(check this in PDF content)
24
Connolly SJ, Ezekowitz MD, Salim Yusuf et al and the RE-LY Steering Committee and Investigators. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med,2009, September 17, 361: 1139-1151. DOI: 10.1056/NEJMoa090556123.
(check this in PDF content)
25
Manesh RP, Mahaffey KW, Jyotsna Garg et al and the ROCKET AF Steering Committee, for the ROCKET AF Investigators. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med,2011, 365: 883-891.
(check this in PDF content)
26
Vranckx P, White HD, Huang Z et al. Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. J Am CollCardiol, 2016, 67(18): 2135-44. doi: 10.1016/j.jacc.2016.02.05.
(check this in PDF content)
27
Choi JH, Seo JM, Lee DH et al. Clinical utility of new bleeding criteria: a prospective study of evaluation for the Bleeding Academic Research Consortium definition of bleeding in patients undergoing percutaneous coronary intervention. J Cardiol, 2015, 65(4): 324-9. doi: 10.1016/j.jjcc.2014.06.011.
(check this in PDF content)
28
Гуськова Е.В., Панченко Е.П., Комаров А.Л. и соавт. Показатели гемостаза и прогноз тромботических и геморрагическиих осложнений у больных ИБС после плановых чрескожных коронарных вмешательств. Кардиологический вестник, 2015, 10(3): 54-63.
(check this in PDF content)
29
van dеr Meer FJ, Rosendaal FR, Vandenbroucke JP et al. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Inter Med, 1993, 153: 1557-1562.
(check this in PDF content)
30
Palareti G, Leali N, Coccheri S et al. Hemorrhagic complications of oral anticoagulant therapy: results of a prospective multicenter study ISCOAT (Italian Study on Complications of Oral Anticoagulant Therapy). G Ital Cardiol, 1997, 27(3): 231-43.
(check this in PDF content)
31
Gorter JW. Major bleeding during anticoagulation after cerebral ishemia: patterns asnd risk factors. Stroke Prevention in Reversible Ishemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology,1999, 53(6): 1319-27.
(check this in PDF content)
32
Gullov AL, Koefoed BG, Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. Arch Intern Med,1999, 159(12): 1322-1328.
(check this in PDF content)
33
Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. N Engl J Med,1995, 333(1): 5-10.
(check this in PDF content)
34
Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet,1996, 348: 423-428.
(check this in PDF content)
35
Fitzmaurice DA, Accetta G, Haas S, et al. GARFIELDAF Investigators «Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists. Br J Haematol, 2016 Aug, 174(4): 610-23.
(check this in PDF content)
36
Diener HC. Executive Steering Committee of the SPORTIFF III and V Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis, 2006, 21(4): 279-93.
(check this in PDF content)
37
Gage BF, Eby C, Johnson JA et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther, 2008, 84: 326-331.
(check this in PDF content)
38
D’Andrea G, D’Ambrosio RL, Di Perna P et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood,2005, 105(2): 645-9. Epub 2004 Sep 9.
(check this in PDF content)
39
Sconce EA, Khan TI, Wynne HA et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a newdosing regimen. Blood, 2005, 106(7): 2329-33.
(check this in PDF content)
40
Shirayama T, Shiraishi H, Kuroyanagi A et al. Interaction between Warfarin and Proton Pump Inhibitors. International Journal of Clinical Medicine, 2014, 5: 836-843.
(check this in PDF content)
41
Uno T, Sugimoto K, Sugawara K and Tateishi T. The Role of Cytochrome P2C19 in R-Warfarin Pharmacokinetics and Its Interaction with Omeprazole. Therapeutic Drug Monitoring, 2008, 30: 276-281.
(check this in PDF content)
42
Hata M, Shiono M, Akiyama K et al. Incidence of drug interaction when using proton pump inhibitor and warfarin according to cytochrome P450 2C19 (CYP2C19) genotype in Japanese. Thorac Cardiovasc Surg, 2015, 63(1): 45-50.
(check this in PDF content)
43
McDonald MG, Au NT, Wittkowsky AK, Rettie AE. Warfarin-amiodarone drug-drug interactions: determination of [I](u)/K(I,u) for amiodarone and its plasma metabolites. Clin Pharmacol Ther, 2012, 91(4): 709-1.
(check this in PDF content)
44
Heimark LD, Wienkers L, Kunze K et al. The mechanism of the interaction between amiodarone and warfarin in humans». Clin Pharmacol Ther, 1992, 51(4): 398-407.
(check this in PDF content)
45
Holbrook AM, Pereira JA, Labiris R et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med, 2005, 165(10): 1095-106.
(check this in PDF content)
46
Flaker G, Lopes RD, Hylek E et al. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol, 2014, 64(15): 1541-50.
(check this in PDF content)
47
Кропачева Е.С., Боровков Н.Н., Вавилова Т.В. и др. Быстрые темпы насыщения варфарином — предиктор развития чрезмерной гипокоагуляции. Модернизация алгоритма подбора дозы варфарина. Атеротромбоз,2015, 1: 74-86.
(check this in PDF content)
48
Prudhvi K, Rao VD, Jain RK. Study on incidence of bleeding in hospitalized patients after antithrombotic therapy at a tertiary care hospital. J Assoc Physicians India, 2013, 61(2): 110-3.
(check this in PDF content)
49
Mennuni MG, Halperin JL, Bansilal S et al. Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). Am J Cardiol, 2015, 116(1): 37-42.
(check this in PDF content)
50
Zhao HJ, Zheng ZT, Wang ZH. «Triple therapy» rather than «triple threat»: a meta-analysis of the two antithrombotic regimensafter stent implantation in patients receiving long-term oral anticoagulant treatment. Chest,2011, 139(2): 260-70.
(check this in PDF content)
51
Barbieri L, Verdoia M, Schaffer A et al. Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies. Cardiovasc Drugs Ther,2016, 30(6): 611-622.
(check this in PDF content)
52
Manzano-FernЗndez S, Pastor FJ, MarТn F et al. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest,2008, 134(3): 559-67.
(check this in PDF content)
53
Khurram Z, Chou E, Minutello R. et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol, 2006 Apr, 18(4): 162-4.
(check this in PDF content)
54
Saheb KJ, Deng BQ, Hu QS et al. Triple antithrombotic therapy versus double antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients requiring chronic oral anticoagulation: a meta-analysis. Chin Med J (Engl),2013, 126(13): 2536-42.
(check this in PDF content)
55
D’Ascenzo F, Taha S, Moretti C. Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention. Am J Cardiol, 2015, 115(9): 1185-93.
(check this in PDF content)
56
Chen CF, Chen B, Zhu J, Xu YZ. Antithrombotic therapy after percutaneous coronary intervention in patients requiring oral anticoagulant treatment. A meta-analysis. Herz,2015, 40(8): 1070-83. doi: 10.1007/s00059-015-4325-0.
(check this in PDF content)
57
Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J.ю 2016, 37(38): 2893-2962. DOI: https: //doi.org/10.1093/eurheartj/ehw210.
(check this in PDF content)